MIRA MIRA Pharmaceuticals
- 1.290
- +0.020+1.57%
- 1.350
- +0.060+4.65%
MIRA Pharmaceuticals News
MIRA Pharmaceuticals Appoints New Board Member and Chairman
Express News | Mira Pharmaceuticals Announced The Selection Of The Centre For Human Drug Research In Leiden, The Netherlands, As The Site For Its Phase I/IIa Clinical Trial Of Ketamir-2, A Novel Oral Ketamine Analog
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
US Manufacturing Index Rises To 43, Highest Since 2020
MIRA Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Trending Stocks Today | Pixie Dust Technologies Shoots up 186.56% Post-Market
12 Health Care Stocks Moving In Friday's After-Market Session
Express News | Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Gives Stock $17.75 Price Valuation, Says Co Is Creating A THC Analog That Has The Same Benefits As THC Without The Negative Side Effects
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
Express News | Mira Pharmaceuticals - Remains on Track to Submit Ind Application by End of 2024, With Phase I Clinical Trials Expected to Begin in Q1 2025
Express News | Mira Pharmaceuticals Inc - Reports Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments in Preclinical Study
Mira Pharmaceuticals Analyst Ratings
Mira Pharmaceuticals Initiated With a Buy at Rodman & Renshaw
Express News | Mira Pharmaceuticals - May Offer,Sell Shares of Common Stock of up to $75 Mln From Time to Time
Why Mira Shares Are Trading Higher Today
Express News | MIRA Pharmaceuticals Shares Are Trading Higher After the Company Announced New Preclinical Data for Ketamir-2,
Reported Earlier: MIRA Pharmaceuticals To Present New Preclinical Data Showing 100% Reversal Of Neuropathic Pain For Ketamir-2 At 18th Annual Pain Therapeutics Summit In Boston On October 28-29, 2024
MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
Sharp Sword! The FTC sues three major pharmaceutical 'middlemen', vowing to correct the distorted chain of interests.
①The USA FTC announced on its official website that it has filed a lawsuit against three major pharmaceutical benefit managers and their affiliated organizations, accusing them of engaging in anti-competitive and unfair rebate practices; ② The FTC also "explicitly stated" in the declaration that it is deeply concerned about the roles played by Eli Lilly, Novo-Nordisk, and Sanofi, insulin pharmaceutical companies, and may suggest in future enforcement actions to prosecute these pharmaceutical manufacturers.
Peering Into Mira Pharmaceuticals's Recent Short Interest
Analysis
Price Target
No Data
No Data